“Finally, patients have hope for treating this disease,” said Mary O’Donnell, President and CEO of the Amyloidosis Foundation. “The Assistance Fund’s financial assistance program for hereditary (hATTR) amyloidosis will provide extremely important support for patients who may otherwise be unable to seek treatment due to high out-of-pocket costs.”
They provide financial assistance for medication copays, health insurance premiums, and basic healthcare needs to patients with certain disease types.